Jian Zhang1, Mingzhi Long2, Yichao Yu3. 1. The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. 2. The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China. 3. The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China.
Abstract
BACKGROUND: Blood lipid management is one of the effective strategies for coronary heart disease, and statins are the first-line lipid-lowering drugs. Low density lipoprotein cholesterol (LDL-C) drop brings about cardioprotective effects. Proprotein convertase subtilisin kexin type 9 (PCSK9) is known to increase LDL-C, thus hazarding LDL-C reduction-induced benefits. To date, how PCSK9 responds to various lipid-lowering strategies has not been fully clarified. METHODS: This study involves patients with stable angina and aims to explore and clarify the short-term impacts of rosuvastatin and ezetimibe, alone or in combination, on circulating PCSK9. A total of 68 patients with stable angina were enrolled and 60 eligible patients were randomly assigned into 3 groups (20 subjects in each). Patients in different groups were treated for a period of 14 days with rosuvastatin 10 mg/d, ezetimibe 10 mg/d, and rosuvastatin 10 mg/d plus ezetimibe 10 mg/d, respectively. Concentrations of bloodLDL-C and PCSK9 levels were measured at baseline and at the 14th day after treatment. RESULTS: Both rosuvastatin and ezetimibe could reduce the LDL-C levels, and rosuvastatin displayed a stronger cholesterol-lowering effect than ezetimibe. Moreover, when combined, they yielded even greater efficacy in lowering LDL-C, as compared with either rosuvastatin or ezetimibe mono-treatment (P<0.05). Rosuvastatin therapy (alone or combined with ezetimibe) caused significant rise in circulating PCSK9. Nevertheless, no significant growth of PCSK9 levels (P=0.558) was observed during ezetimibe treatment. At the 14th day, no difference in PCKS9 levels was observed between the rosuvastatin group and the combination-therapy group (P=0.906). CONCLUSIONS:Rosuvastatin plus ezetimibe therapy is more effective in reducing LDL-C levels as compared with either rosuvastatin or ezetimibe mono-medication. Meanwhile, such combination strategy does not further increase the levels of circulating PCSK9 compared to rosuvastatin mono-intervention, thus maintaining maximal clinical benefits from lipid-lowering.
RCT Entities:
BACKGROUND: Blood lipid management is one of the effective strategies for coronary heart disease, and statins are the first-line lipid-lowering drugs. Low density lipoprotein cholesterol (LDL-C) drop brings about cardioprotective effects. Proprotein convertase subtilisin kexin type 9 (PCSK9) is known to increase LDL-C, thus hazarding LDL-C reduction-induced benefits. To date, how PCSK9 responds to various lipid-lowering strategies has not been fully clarified. METHODS: This study involves patients with stable angina and aims to explore and clarify the short-term impacts of rosuvastatin and ezetimibe, alone or in combination, on circulating PCSK9. A total of 68 patients with stable angina were enrolled and 60 eligible patients were randomly assigned into 3 groups (20 subjects in each). Patients in different groups were treated for a period of 14 days with rosuvastatin 10 mg/d, ezetimibe 10 mg/d, and rosuvastatin 10 mg/d plus ezetimibe 10 mg/d, respectively. Concentrations of blood LDL-C and PCSK9 levels were measured at baseline and at the 14th day after treatment. RESULTS: Both rosuvastatin and ezetimibe could reduce the LDL-C levels, and rosuvastatin displayed a stronger cholesterol-lowering effect than ezetimibe. Moreover, when combined, they yielded even greater efficacy in lowering LDL-C, as compared with either rosuvastatin or ezetimibe mono-treatment (P<0.05). Rosuvastatin therapy (alone or combined with ezetimibe) caused significant rise in circulating PCSK9. Nevertheless, no significant growth of PCSK9 levels (P=0.558) was observed during ezetimibe treatment. At the 14th day, no difference in PCKS9 levels was observed between the rosuvastatin group and the combination-therapy group (P=0.906). CONCLUSIONS:Rosuvastatin plus ezetimibe therapy is more effective in reducing LDL-C levels as compared with either rosuvastatin or ezetimibe mono-medication. Meanwhile, such combination strategy does not further increase the levels of circulating PCSK9 compared to rosuvastatin mono-intervention, thus maintaining maximal clinical benefits from lipid-lowering.
Entities:
Keywords:
Stable angina; ezetimibe; low density lipoprotein cholesterol (LDL-C); proprotein convertase subtilisin kexin type 9 (PCSK9); rosuvastatin
Authors: Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton Journal: Proc Natl Acad Sci U S A Date: 2005-04-01 Impact factor: 11.205
Authors: Manuel F Jiménez-Navarro; Francisco López-Jiménez; Gregory Barsness; Ryan J Lennon; Gurpreet S Sandhu; Abhiram Prasad Journal: Heart Date: 2015-04-16 Impact factor: 5.994
Authors: H H Knapp; H Schrott; P Ma; R Knopp; B Chin; J M Gaziano; J M Donovan; S K Burke; M H Davidson Journal: Am J Med Date: 2001-04-01 Impact factor: 4.965
Authors: Linda M Sanderson; Mark V Boekschoten; Beatrice Desvergne; Michael Müller; Sander Kersten Journal: Physiol Genomics Date: 2009-12-15 Impact factor: 3.107
Authors: Holly E Careskey; R Aleks Davis; William E Alborn; Jason S Troutt; Guoqing Cao; Robert J Konrad Journal: J Lipid Res Date: 2007-11-21 Impact factor: 5.922
Authors: Yue-Wei Qian; Robert J Schmidt; Youyan Zhang; Shaoyou Chu; Aimin Lin; He Wang; Xiliang Wang; Thomas P Beyer; William R Bensch; Weiming Li; Mariam E Ehsani; Deshun Lu; Robert J Konrad; Patrick I Eacho; David E Moller; Sotirios K Karathanasis; Guoqing Cao Journal: J Lipid Res Date: 2007-04-20 Impact factor: 5.922